Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

Phase 4 Unknown 1 enrolled Asan Medical Center Novartis Korea Ltd. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Long-term (up to 3 years) clinical and hormonal outcomes in acromegalic patients with treated surgery with or without long acting somatostatin analogues.

Timeline

Start: 2014-03
Primary completion: 2018-12
Completion: 2019-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Octreotide	Peptide	20 mg	Intramuscular
Subject	Octreotide	Peptide	30 mg	Intramuscular

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

Summary

Timeline

Drugs

Indications